In this study, we demonstrated combination treatment of sorafenib and metformin could significantly suppress the proliferation of HCC cells through inhibition of the p62-Keap1-Nrf2/HO-1 pathway in vitro and in vivo. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.